Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
(PinkSheets:PPCB),(Pinksheets:PPCB),(NASDAQ:PPCB), MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock, par value $0.001 per share, […]